Conformal key facts
- Developer of a medical implant device designed to prevent stroke in patients with atrial fibrillation.
- Conformal’s last known valuation is $316.0M (Jul 2025).
- It has raised $165.9M; the latest was Merger/Acquisition ($67.0M) in Feb 2026.
- Notable investors include Fidelity Management & Research Company, The Ropart Asset Management Funds, Angel Physicians Fund, Catalyst Health Ventures, Excelestar Ventures — 6 tracked in total.
- Status: Acquired/Merged (Operating Subsidiary).
- ·Watch Conformal: the Monday email on marks, rounds and moves
Conformal funding rounds
No funding rounds for Conformal are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Conformal valuation
Conformal's last known valuation is $316 million, from Jul 2025. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Conformal investors
6 investors are on record for Conformal, including Fidelity Management & Research Company, The Ropart Asset Management Funds, Angel Physicians Fund and Catalyst Health Ventures.
About Conformal
Developer of a medical implant device designed to prevent stroke in patients with atrial fibrillation. The company's device addresses non-valvular atrial fibrillation and tailors its design to each patient's anatomy, meeting the demands of atrial appendage closure, enabling doctors and medical professionals to treat patients prone to strokes and save lives.
- Sector
- Healthcare
- HQ
- Nashua, NH, United States
- Founded
- 2016
- Employees
- 48
- Website
- conformalmedical.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Conformal’s last known valuation, Jul 2025. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.